These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9105227)

  • 41. Underreporting in traffic accident data, bias in parameters and the structure of injury severity models.
    Yamamoto T; Hashiji J; Shankar VN
    Accid Anal Prev; 2008 Jul; 40(4):1320-9. PubMed ID: 18606262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanding clinical applications of population pharmacodynamic modelling.
    Minto C; Schnider T
    Br J Clin Pharmacol; 1998 Oct; 46(4):321-33. PubMed ID: 9803979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The parasite capacity of the host population].
    Kozminskiĭ EV
    Parazitologiia; 2002; 36(1):48-59. PubMed ID: 11965643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing methods for analyzing overdispersed binary data in aquatic toxicology.
    Noble RB; Bailer AJ; Noe DA
    Environ Toxicol Chem; 2009 May; 28(5):997-1006. PubMed ID: 19049261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative efficiencies of randomized concentration- and dose-controlled clinical trials.
    Endrenyi L; Zha J
    Clin Pharmacol Ther; 1994 Sep; 56(3):331-8. PubMed ID: 7924129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamic principles and the time course of immediate drug effects.
    Holford N
    Transl Clin Pharmacol; 2017 Dec; 25(4):157-161. PubMed ID: 32095468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of the 1990 Hong Kong legislation for restriction on sulfur content in fuel.
    Wong CM; Rabl A; Thach TQ; Chau YK; Chan KP; Cowling BJ; Lai HK; Lam TH; McGhee SM; Anderson HR; Hedley AJ
    Res Rep Health Eff Inst; 2012 Aug; (170):5-91. PubMed ID: 23316618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy volunteers.
    Hering WJ; Ihmsen H; Langer H; Uhrlau C; Dinkel M; Geisslinger G; Schüttler J
    Anesthesiology; 1996 Dec; 85(6):1290-9. PubMed ID: 8968176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computational tools for fitting the Hill equation to dose-response curves.
    Gadagkar SR; Call GB
    J Pharmacol Toxicol Methods; 2015; 71():68-76. PubMed ID: 25157754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats.
    Dingemanse J; Voskuyl RA; Langemeijer MW; Postel-Westra I; Breimer DD; Meinardi H; Danhof M
    Br J Pharmacol; 1990 Jan; 99(1):53-8. PubMed ID: 2331575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
    Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of models to analyze mortality data and derive concentration-time response relationship of inhaled chemicals.
    Péry AR; Troise A; Tissot S; Vincent JM
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):124-8. PubMed ID: 20172012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stochastic simulation for death probability of bacterial population considering variability in individual cell inactivation time and initial number of cells.
    Koyama K; Abe H; Kawamura S; Koseki S
    Int J Food Microbiol; 2019 Feb; 290():125-131. PubMed ID: 30326383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and analysis of in vitro antitumor pharmacodynamic studies.
    Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity to initial values in full non-parametric maximum-likelihood estimation of the two-parameter logistic model.
    Nader IW; Tran US; Formann AK
    Br J Math Stat Psychol; 2011 May; 64(Pt 2):320-36. PubMed ID: 21492136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.